How Big Is the Threat to This Johnson & Johnson Blockbuster?
Growth for Johnson & Johnson's (JNJ) blockbuster Zytiga is being weighed down by Medivation (MDVN) and Astellas (ALPMY) Xtandi.
Why I Bought Exelixis
The author shares his opinion why the recent drop in Exelixis is an incredible buying opportunity.
Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Medivation (MDVN) may see sales of its prostate cancer drug Xtandi hit a blockbuster run rate this year.
Was Medivation's Quarter a Disaster?
Medivation (MDVN) shares sank more than 10% on news of slowing sales growth for its prostate cancer drug Xtandi; however, an FDA decision and potential milestones may support the company into year end.
3 Investing Lessons From Dendreon
Dendreon, the maker of the the prostate cancer drug Provenge, has been marginalized by newer drugs from Johnson & Johnson, Medivation, and Astellas Pharma. What three valuable investing lessons can investors learn from Dendreon’s mistakes?
Can an EU Approval Save This Dying Biotech?
Dendreon, the creator of Provenge, recently rallied on an approval in Europe. However, is it too little, too late for this struggling company?
3 Humongous Health-Care Stocks This Week
These health care stocks made big gains to open the new month.
Optimer Pharmaceuticals Shares Soar... for the Right Price, That Is!
A curious quartet of potential bidders sends Optimer's share price soaring to the heavens, but is it really worth the risk?